What is the Foghorn Therapeutics Inc. stock price forecast?

Foghorn Therapeutics Inc. is currently trading at $4.71. View real-time AI analysis on Alpha Lenz.

What is Foghorn Therapeutics Inc. insider trading activity?

View the latest insider trading data for Foghorn Therapeutics Inc. on Alpha Lenz.

What is Foghorn Therapeutics Inc.'s P/E ratio?

Foghorn Therapeutics Inc.'s P/E ratio is -4.0.

Foghorn Therapeutics Inc.

NASDAQ · FHTX

$4.71-0.02(-0.53%)Live

Ask about Foghorn Therapeutics Inc.'s future dividend policy...

Alpha Chat Insight

“Foghorn Therapeutics Inc. trades at a P/E of -4.0 (undervalued) with strong ROE of 96.5%. 3Y revenue CAGR of 17.1% highlights clear growth momentum.”

Ask for details →

Company Overview

Foghorn Therapeutics Inc. is a biotechnology company that engages in the development of a new class of cancer treatments, utilizing its proprietary Gene Traffic Control platform. The primary aim of the company is to decode the regulatory regions of the genome to discover and develop innovative therapies that target the chromatin regulatory system. Foghorn's focus on chromatin biology enables it to address difficult-to-treat indications by modulating gene expression patterns central to cancer development. Operating primarily within the realm of oncology, Foghorn Therapeutics seeks to bring novel approaches to cancer treatment, impacting areas such as targeted therapies and personalized medicine. The company's efforts are significant in the biotechnology landscape, pushing the boundaries of cancer research by exploring the relationship between gene regulation and disease. Headquartered in Cambridge, Massachusetts, Foghorn continues to advance its pipeline with the hope of delivering new therapeutic options to patients worldwide.

CEOMr. Adrian H. B. Gottschalk

Websitehttps://foghorntx.com

SectorHealthcare

IndustryBiotechnology

Employees112

Company Statistics

FY 2025

Profile

$297.90MMarket Cap

$30.91MRevenue

0.00Shares Out

112Employees

Margins

N/AGross

-241.01%EBITDA

-265.64%Operating

-240.33%Pre-Tax

-240.33%Net

Valuation

-4.01P/E

-2.75P/B

9.64EV/Sales

-3.47EV/EBITDA

-3.46P/FCF

Growth (CAGR)

17.14%Rev 3Yr

135.14%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-30.82%ROA

96.45%ROE

-34.06%ROIC

Financial Health

$80.88MCash & Cash Equivalents

$225.73MNet Debt

-282.58%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Foghorn Therapeutics Inc. trades at a P/E of -4.0 (undervalued) with strong ROE of 96.5%. 3Y revenue CAGR of 17.1% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Foghorn Therapeutics Inc. (ticker: FHTX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 112 employees. Market cap is $298M.

The current price is $4.715 with a P/E ratio of -4.01x and P/B of -2.75x.

ROE is 96.45% and operating margin is -265.64%. Annual revenue is $31M.